London Healthcare Week: As the company gears up for its first phase 3 trials, MindMed's CEO says he sees a tailwind of regulatory support for the psychedelics space

blonca9
Nov 21, 2024
1 min read

Updated: Nov 27, 2024

Robert Barrow discusses MindMed's LSD based program that is going into phase 3 studies for generalized anxiety disorder and major depressive disorder and an earlier stage R(-)-MDMA program for autism spectrum disorder.

Recent Posts

See All

The leaders of London based LabGenius Therapeutics discuss a recent ESMO IO poster for their Nectin-4 x CD3 T-cell engager, and a new expanded collaboration with Sanofi on antibody optimization

Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today

Kymera Therapeutics' Founder & CEO Nello Mainolfi recaps Monday's STAT6 data and discusses the next steps in development

London Healthcare Week: As the company gears up for its first phase 3 trials, MindMed's CEO says he sees a tailwind of regulatory support for the psychedelics space

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight